L-arginine Supplementation In Peripheral Arterial Disease: No Benefit And Possible Harm
| Effect | None |
| Trial Design | Double blind |
| Trial Length | 1-6 months |
| Number of Subjects | 133 |
| Gender | Both Genders |
| Age Range | 65+ |
3g arginine daily for 6 months in persons with peripheral artery disease (intermittent claudication in this study) noted that supplementation was actually adverse to blood flow and symptoms of claudition as assessed by functional testing on a treadmill (reducing a 28.3% improvement to 11.5%).